HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc.

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based ...

SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing ...

LEVERKUSEN, Germany & PHILADELPHIA & TOKYO--(BUSINESS WIRE)--Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, ...

iXCells Biotechnologies focuses on creating a broad portfolio of iPSC-derived off-the-shelf and custom cell models from healthy and patient donors to make "clinical-trials-in-a-plate" a reality SAN ...

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting ...

Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes 17.05.2022 / 07:30 The issuer is solely responsible ...

In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) ...

The New York Blood Center Enterprises and the Chan Zuckerberg Biohub are collaborating to derive induced pluripotent stem cell lines from cord blood, using NYBCe’s inventory of over 30,000 units, ...

SEATTLE--(BUSINESS WIRE)--Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, today announced the ComboMat™ platform, a proprietary human iPSC-derived cardiomyocyte ...